triamcinolone acetonide + fluconazole

This investigational combination therapy, developed by Cairo University, is designed for the treatment of chronic paronychia. It consists of a solution containing 0.5% triamcinolone acetonide, a synthetic corticosteroid with potent anti-inflammatory properties, and 0.2% fluconazole, a triazole antifungal agent. The therapy is administered via intralesional injection directly into the affected nail fold. Triamcinolone acetonide works by binding to glucocorticoid receptors to reduce the inflammation and swelling characteristic of chronic paronychia, while fluconazole targets fungal pathogens, such as *Candida* species, which are frequently implicated in the condition's pathogenesis. This combination is currently being evaluated in a Phase 3 clinical trial (NCT07311759) to compare its efficacy and safety against standard topical steroid and antifungal treatments.

Other names

intralesional triamcinolone acetonide and fluconazoletriamcinolone acetonide 0.5% in fluconazole 0.2% solution